Company / Net Income
Voyager Therapeutics, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$132.3M
FY2025
5-year range
-$71.2M / $132.3M
FY2021-FY2025
Trend
+385.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income changed +385% YoY in FY2025, a notable deviation from the 9-year average annual change of +16%.
Based on SEC 10-K filings.
$132M in FY2025 with a 3-year CAGR of +53.3%.
Improved from -$71M to $132M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- +53.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +53.3%, indicating consistent growth.
- In FY2025, net income increased 385.1% year-over-year.
- Lowest net income in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.34 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $132.3M | +385.1% |
| FY2024 | -$46.4M | +34.8% |
| FY2023 | -$71.2M | -293.8% |
| FY2022 | $36.7M | +184.3% |
| FY2021 | -$43.6M | +50.6% |
| FY2020 | -$88.3M | -24.9% |
| FY2019 | -$70.7M | -75.9% |
| FY2018 | -$40.2M | -35.5% |
| FY2017 | -$29.7M | -81.8% |
| FY2016 | -$16.3M | -325.7% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026